Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (OTC: WINT) said it may receive substantial milestone payments after its licensing partner initiated renewed development activity on the company’s acute pulmonary therapies for …
Windtree Signals Possible Windfall as Partner Revives Lifesaving Infant Lung Treatments Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (OTCID: WINT) has strengthened its intellectual property position with newly allowed and granted patents in Canada, Mexico, and Israel, reinforcing the company’s long-term strategy …
Windtree Expands Global Patent Portfolio as Heart Failure Pipeline Gains Momentum Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (OTC: WINT) will receive $7.5 million in cash and securities from TESI (OTC: TESI) after the two companies agreed to terminate discussions over a …
Windtree Secures $7.5M as Planned Environmental Services Deal Is Called Off Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (OTCID: WINT) announced that all ten proposals presented at its August 28 Special Stockholder Meeting were approved, clearing the way for a major strategic …
Windtree Stockholders Approve Strategic Pivot Toward Environmental Services Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that interim Phase 2 trial data for its investigational therapy istaroxime will be presented at the Heart Failure Society of America’s …
Windtree Therapeutics Reports Promising Interim Results for Heart Failure Drug Candidate Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported encouraging interim results from its ongoing SEISMiC C Phase 2 trial evaluating istaroxime in patients with SCAI Stage C cardiogenic shock, …
Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced major reductions in its outstanding Series C and Series D preferred shares, positioning the company to limit future equity dilution as it …
Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced two major equity financing agreements totaling up to $520 million, positioning the company to significantly expand its holdings of BNB cryptocurrency, …
Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has entered into a strategic partnership with Kraken, a leading global cryptocurrency platform, to support custody, trading, and over-the-counter (OTC) services for …
Windtree Taps Kraken to Power BNB Crypto Treasury Strategy Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced a transformative financing agreement this week, unveiling plans to raise up to $200 million to launch a first-of-its-kind BNB crypto treasury …
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal Read More